Introduction
Genetic immunization strategies have become attractive for the development of melanoma vaccines, because a number of antigens recognized by cellular components of the immune system have been identified at the molecular level in melanoma patients. These melanoma antigens include normal cellular proteins such as the tyrosinase family of enzymes involved in melanin synthesis which are endogenously expressed in melanocytes and melanoma cells. 1 Previous experiments demonstrated that genetic immunization of C57BL/6 mice with cDNA encoding autologous murine tyrosinase-related protein 2 (TRP2) as a model antigen was unable to induce significant protective immunity against B16 melanoma cells naturally expressing TRP2. 2 Subsequently, we and others found that genetic immunization of mice with cDNA encoding xenogeneic homologous human TRP2 was able to circumvent peripheral tolerance and mediate marked protective immunity against metastatic growth of B16 melanoma cells. 3, 4 Importantly, immunization with xenogeneic human, but not with autologous murine TRP2 cDNA was able to stimulate CD8 + T cells in vivo recognizing the H2-K derives from an evolutionary conserved region of both murine and human TRP2 corresponding to amino acids 180-188. This peptide has been identified as a melanoma rejection antigen in C57BL/6 mice using a K b -restricted CTL line specific for B16 melanoma cells. 5 Additionally, we found that mice immunized with human, but not with murine TRP2 cDNA produced antibodies reactive with human TRP2 and cross-reactive with murine TRP2. Furthermore, induction of immunity to TRP2 was associated with fur depigmentation as a sign of autoimmunemediated destruction of melanocytes.
We hypothesized that immunization with murine TRP2 is not effective because it does not stimulate a CD4 + T-helper response. Human TRP2 instead differs from murine TRP2 by about 20% at the amino acid level and may therefore accidentally provide strong CD4
+ T-helper cell epitopes which derive from non-homologous sequences. In the present study, we investigated whether it would be possible to induce antigen-specific immunity and protection against a challenge with B16 melanoma cells with the autologous murine TRP2 sequence if it were linked to a foreign protein capable of providing CD4 T cell help. For our experiments, we chose the marker gene enhanced green fluorescent protein (EGFP) because we have observed strong humoral and cellular immune responses in C57BL/6 mice and can directly visualize the expression of EGFP-fusion proteins in transduced cells using fluorescence microscopy.
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Results
Genetic immunization with cDNA encoding the model self-antigen TRP2 linked to immunogenic helper sequences derived from EGFP induces autoimmunity
The melanocytic enzyme TRP2 is a type II transmembrane glycoprotein translationally inserted into the endoplasmic reticulum via an N-terminal signal sequence corresponding to amino acids 1-24. Amino acids 475-495 are strongly hydrophobic and represent the transmembrane domain. The C-terminal cytoplasmic tail corresponding to amino acids 496-517 contains trafficking signals allowing for localization of TRP2 to melanosomes. We constructed an expression plasmid encoding a fusion protein between EGFP and aa30-517 of murine TRP2 (pCMV-EGFP.mTRP2) using PCR techniques. Analysis of transiently transfected 293 cells by immunocytochemistry and fluorescence microscopy confirmed expression of both EGFP and mTRP2. In initial experiments, C57BL/6 mice were genetically immunized with pCMV-EGFP.mTRP2 using the gene gun. Control groups of mice received the plasmids pCMV-EGFP or pCMV-mTRP2. After five weekly gene gun shots, we observed loss of coat color in the shaved and bombarded areas of the abdominal skin of all mice immunized with pCMV-EGFP.mTRP2 ( Figure 1 ). Subsequently, patchy depigmentation also occurred on the back in some of the mice. Fur depigmentation was similar to that observed previously in mice immunized with pCMV-hTRP2. 3, 4 In contrast, none of the mice immunized with pCMV-mTRP2 or pCMV-EGFP alone showed any sign of depigmentation. This result suggested that immunization with TRP2 linked to the immunogenic protein EGFP is able to stimulate autoimmunity capable of destroying melanocytes. 
Gene Therapy
Linkage of EGFP-derived helper sequences breaks peripheral T cell tolerance and induces T cells recognizing TRP2
We hypothesized that stimulation of EGFP-specific CD4 + T cells provided help for the induction of autoreactive TRP2-specific CD8 + T cells in our initial experiments leading to autoimmune depigmentation. We therefore tested splenocytes harvested from immunized mice for recognition of the synthetic H2-K b -binding peptide TRP2 aa180-188 using IFN␥-ELISPOT assays. Unfortunately, EGFPderived peptide epitopes recognized by EGFP-specific CTL have not been identified to date. We could clearly detect TRP2-specific reactivity in splenocytes from mice immunized with pCMV-EGFP.mTRP2 using the gene gun ( Figure 2 ). Induction of TRP2-reactive T cells was similar to that in mice immunized with pCMV-hTRP2. In contrast, mice immunized with pCMV-mTRP2 or pCMV-EGFP alone did not develop any reactivity to the TRP2 aa180-188 peptide. This important finding indicated that linkage of EGFP-derived helper sequences broke peripheral T cell tolerance and was able to induce TRP2-specific T cells in vivo, confirming our initial hypothesis. In a separate set of experiments we investigated the requirement for direct linkage of EGFP and mTRP2. Groups of mice were immunized with a combination of pCMV-EGFP and pCMV-mTRP2 using the gene gun. Both plasmids were precipitated on to gold beads simultaneously and are therefore expressed in the same cells in vivo. Control groups of mice received either pCMV-EGFP.mTRP2, pCMV-EGFP, or pCMV-mTRP2 alone. Fur depigmentation and TRP2-specific T cell reactivity was only observed in mice receiving the plasmid encoding the fusion protein between EGFP and TRP2. This result agreed with our previous experience using a recombinant adenovirus encoding murine TRP2 (Ad-mTRP2) for genetic immunization. Although the adenoviral envelope proteins included in this vector naturally stimulate high levels of antigen-specific IgG in mice indicating a vigorous adenovirus-specific CD4
+ T cell response, we never detected TRP2-specific T cell reactivity in mice immunized with Ad-mTRP2. In contrast, injection of a recombinant adenovirus encoding the fusion protein EGFP.mTRP2 (Ad-EGFP.mTRP2) stimulated strong TRP2-specific T cell reactivity in ELISPOT assays. These experiments indicate that circumvention of T cell tolerance requires a direct linkage between EGFP-derived helper sequences and the self-antigen TRP2.
Genetic immunization with EGFP.mTRP2 induces specific antibodies recognizing EGFP, but not mTRP2
Subsequently, we investigated the induction of humoral immune responses to EGFP and TRP2. Using a sandwich ELISA, we measured high levels of EGFP-specific IgG antibodies in sera harvested from mice immunized with pCMV-EGFP or pCMV-EGFP.mTRP2 (Figure 3a ). Since isotype switching critically requires help from antigenspecific CD4
+ T cells, this result indirectly confirmed the induction of EGFP-specific CD4 + T cells in vivo. In theory, EGFP-specific CD4 + T cell help should also be able to stimulate the induction of TRP2-specific antibodies. Since we do not have purified TRP2 protein, we were not able to measure the induction of TRP2-specific antibodies by ELISA. As an alternative, we used a Western blot technique. Cell lysates from B16 melanoma cells naturally expressing mTRP2 and from 293 cells infected with AdmTRP2 or control adenovirus were separated by SDS-PAGE, blotted on to PVDF membranes, and probed with pooled sera from immunized mice as the primary antibody. We found that sera from mice immunized with pCMV-EGFP.mTRP2 did not show reactivity with mTRP2 expressed by B16 melanoma cells or Ad-mTRP2-infected 293 cells (Figure 3b ). Sera from mice immunized with pCMV-EGFP or pCMV-mTRP2 also did not react with mTRP2 (data not shown). In contrast, sera harvested from mice immunized with pCMV-hTRP2 contained crossreactive autoantibodies recognizing the unglycosylated and the fully glycosylated form of mTRP2 which are approximately 55 and 75 kDa in size (Figure 3c ). These results did not provide any evidence that EGFP-derived helper sequences were also able to circumvent mechanisms maintaining TRP2-specific B cell tolerance. One potential explanation for the difference between EGFP.mTRP2 and human TRP2 could relate to the different intracellular localization of their synthesis. The artificial fusion protein EGFP.mTRP2 lacks a signal sequence and is therefore expressed in the cytosol where TRP2 will not be glycosylated. In contrast, unmodified TRP2 contains a signal sequence and is naturally translated as a transmembrane protein into the endoplasmic reticulum, where it is subsequently glycosylated and traffics to melanosomes. This results in a completely different tertiary structure. We can not exclude that EGFP.mTRP2 stimulates antibodies specific for linear epitopes derived from the primary TRP2 sequence which do not recognize the properly folded, fully glycosylated TRP2 protein.
Genetic immunization with pCMV-EGFP.mTRP2 results in protective immunity against B16 melanoma cells
Previously we demonstrated that genetic immunization with a recombinant adenovirus expressing hTRP2 (AdhTRP2) prevented growth of experimentally induced B16 melanoma lung metastases. In a direct comparison, genetic immunization with the expression plasmid pCMVhTRP2 using the gene gun was less efficient and only reduced the number of melanoma lung metastases. 3 To investigate the induction of protective immunity following genetic immunization with EGFP.mTRP2, we therefore immunized mice with one intraperitoneal injection of Ad-EGFP.mTRP2. Immunization with Ad-EGFP.mTRP2 was as effective as immunization with AdhTRP2 and completely prevented growth of B16 melanoma lung metastases in three independent experiments (Figure 4) . In contrast, injection of Ad-mTRP2 or Ad-EGFP alone or in combination did not prevent growth of B16 melanoma lung metastases. These results demonstrated that linkage of EGFP-derived helper sequences was able to induce a TRP2-specific immune response capable of protecting mice against metastatic growth of B16 melanoma in the lungs.
Role of CD4 and CD8 T cells for the induction of autoimmunity and tumor immunity
In subsequent experiments we investigated the dependence of the vaccine-induced tumor immune defense on the presence of CD4
+ and CD8 + T cells. Groups of wildtype, CD4 and CD8 knockout mice were immunized either with Ad-EGFP.mTRP2 or with control adenovirus. In contrast to wild-type mice, both CD4 and CD8 knockout mice were not protected against metastatic growth of B16 melanoma cells in the lungs following immunization with Ad-EGFP.mTRP2 ( Figure 5 ). This agrees with results of previous experiments showing that immunization with Ad-hTRP2 also does not protect from metastatic growth of melanoma in either CD4 or CD8 knockout mice.
In a subsequent experiment wild-type, CD4 and CD8 knockout mice were immunized five times with pCMV-EGFP.mTRP2 or pCMV-EGFP using the gene gun. While all wild-type mice developed depigmentation at the site of immunization, we did not observe any coat color 
cells. To assess the dependence of the vaccine efficacy on CD4
+ and CD8
+ T cells, genetic immunization with Ad-EGFP.mTRP2 or Ad-EGFP was performed in CD4 knockout or CD8 knockout C57BL/6 mice. Shown are the number of lung metastases in individual mice (dots) and the mean number of metastases in each group (horizontal bar). This experiment was carried out twice with similar results.
Gene Therapy changes in either CD4 or CD8 knockout mice, suggesting that the induction of autoimmune-mediated destruction of melanocytes also depended on the presence of both CD4 + and CD8 + T cells. These observations support our hypothesis, that the efficacy of this immunization strategy critically requires CD4 + and CD8 + T cells.
Discussion
Antigen-specific immunization targeting melanocytic self-antigens recognized by T cells is currently being pursued as a strategy to induce protective immunity against melanoma. Peripheral tolerance to this category of melanoma antigens has recently been directly demonstrated in mice 8 and presents one of the major obstacles for the induction of effective tumor immunity using current vaccine approaches. Employing genetic immunization with TRP2 and EGFP as model antigens, we demonstrate here that linkage of an immunogenic helper sequence to a melanocytic self-antigen is able to break peripheral T cell tolerance, cause autoimmune-mediated destruction of melanocytes, and prevent metastatic growth of melanoma. In the literature, this strategy has to date only been reported for the induction of self-reactive anti-idiotypic antibodies and CD4
+ T cells capable of protecting mice from metastatic growth of a model B cell lymphoma. [9] [10] [11] In our study, we present evidence that the induction of EGFP-specific CD4 + T cells provided help for the induction of TRP2-specific T cells recognizing the H2-K b -binding peptide TRP2 aa180-188 which was identified with tumor-protective CD8 + CTL. 5 Importantly, we show that breaking T cell tolerance depended on a direct linkage between EGFP and TRP2. Delivery of TRP2 alone, even with strongly immunogenic viral vectors appears not to be sufficient. 2, 12 We believe that this requirement for physical linkage of the foreign helper sequence reflects the necessity that both MHC class II-binding peptides recognized by CD4 + T-helper cells and MHC class I-binding peptides recognized by CD8
+ CTL have to be presented by the same antigen-presenting dendritic cell (DC). Cognate interaction of antigen-bearing DC with CD4 + T-helper cells leads to terminal maturation, which appears to be critically required for the ability to stimulate self-reactive CD8 + CTL. 13 This hypothesis is supported by our observations that the vaccine efficacy was abrogated in both CD4 and CD8 knockout mice. Furthermore, we and others have previously reported that delivery of Ad-mTRP2 with cultured dendritic cells enhanced the induction of protective immunity to B16 melanoma via a CD4-dependent mechanism. 14, 15 In agreement with published observations in the B cell lymphoma model, 10 we also observed that delivery of Ad-EGFP.mTRP2 with cultured dendritic cells further enhanced protective tumor immunity against subcutaneous growth of B16 melanoma (unpublished observations). Interestingly, delivery of Ad-EGFP.mTRP2 or Ad-hTRP2 with cultured DC was not associated with fur depigmentation, suggesting that the induction of autoimmunity and tumor immunity do not necessarily correlate.
We believe that TRP2-reactive CD8 + CTL are the principal effector cells mediating tumor immunity and autoimmunity. However, we cannot rule out that TRP2-specific CD4 + T cells also play an important role in the effector phase. We previously found that the protective efficacy of genetic immunization with Ad-mTRP2-trans-duced DC was abrogated when either CD8 + or CD4 + T cells were depleted immediately before and during tumor challenge. Potentially, EGFP-specific CD4 + T cells could also provide help for the induction of TRP2-specific CD4 + T cells. Foreign CD4 + T cell help for the induction of self-reactive CD4 + T cells has recently been directly demonstrated. 11, 16 Future experiments will have to clarify the role of CD4 + T cells in the effector phase of immunemediated tumor rejection.
Interestingly, genetic immunization with pCMV-EGFP.mTRP2 did not induce TRP2-reactive antibodies. This suggested that induction of TRP2-specific cellular immunity alone was able to protect mice against metastatic growth of melanoma and can mediate autoimmune destruction of melanocytes. TRP2-reactive antibodies against human TRP2 with cross-reactivity against murine TRP2 were always observed following immunization with cDNA encoding human TRP2. As mentioned before, one potential explanation for this difference could relate to the fact that the fully glycosylated transmembrane protein TRP2 and the unglycosylated cytosolic EGFP.mTRP2 fusion protein will have completely different tertiary structures. In preliminary experiments, we found that genetic immunization with cDNA encoding EGFP.mTRP2 preceded by a signal sequence allowing for direct translation into the endoplasmic reticulum (ES.EGFP.mTRP2) also led to vitiligo-like fur depigmentation, induction of TRP2-specific T cells, and protection against metastatic growth of B16 melanoma cells (data not shown). Expression of ES.EGFP.mTRP2 in 293 cells and detection of TRP2 in Western blots yields two bands which are approximately 80 and 100 kDa in size, indicating glycosylation of the EGFP-mTRP2 protein. Nevertheless, mice immunized with ES.EGFP.mTRP2 also did not develop significant levels of antibodies which bind to naturally expressed TRP2 in lysates of B16 melanoma cells. In future experiments we will investigate whether incorporation of helper sequences in such a way that the tertiary structure of TRP2 remains largely unaltered will be able to induce antibodies recognizing naturally expressed full-length TRP2 upon immunization. Such a strategy has been successfully employed for the induction of autoantibodies against the self-proteins ubiquitin and TNF␣ using an E. coli-derived recombinant protein which had been genetically engineered to contain a known immunogenic T-helper epitope derived from a foreign antigen within its sequence. 17, 18 In conclusion, we show that a genetic melanoma vaccine consisting of an immunogenic foreign helper sequence linked to a melanocytic self-antigen is able to break peripheral T cell tolerance and induce protective immunity against B16 melanoma in C57BL/6 mice. Most importantly, these results provide the scientific basis for the exploration of similar antigen-specific immunization strategies in future clinical trials for the immunotherapy of melanoma.
Materials and methods
Animals and cell lines
Wild-type, CD4 and CD8 knockout C57BL/6 mice (H-2 b ), 6-12 weeks old, were bred at the Central Animal Facility of the University of Mainz. CD4 and CD8 knockout C57BL/6 mice were purchased from Jackson Laboratories (Bar Harbor, ME, USA). B16 (H-2 b ) is a spontaneously arising murine melanoma (a kind gift of Dr S Rosenberg, National Cancer Institute, Bethesda, MD, USA) and was maintained in DMEM supplemented with 10% heat-inactivated FCS, 2 mm l-glutamine, 50 m 2-mercaptoethanol, 100 IU/ml penicillin, and 100 g/ml streptomycin (all reagents were from Life Technologies, Eggenstein, Germany).
Peptides, recombinant protein, expression plasmids and recombinant adenoviruses
The H-2K b -binding peptide SVYDFFVWL (TRP2 aa180-188 ) derived from the murine melanosomal protein TRP2 was synthesized by standard FMOC chemistry and purified by HPLC in the Peptide Synthesis Facility of the University of Mainz. Peptides were dissolved at 10 g/ml in PBS containing 10% DMSO and stored at Ϫ20°C. Recombinant EGFP was purchased from Clontech (Palo Alto, CA, USA) and stored at Ϫ20°C. The construction of plasmids pCMV-mTRP2 and pCMV-EGFP has been described. 2 Plasmid pCMV-hTRP2 was kindly provided by Dr Shibahara, Tobohu University, Miyagi, Japan. 20 A plasmid expressing a fusion protein between EGFP and aa30-519 of murine TRP2 (pCMV-EGFP.mTRP2) was constructed by joining the cDNA encoding EGFP in frame with codons 30-517 of murine TRP2 using PCR techniques. Expression of both EGFP and murine TRP2 was confirmed in transiently transfected 293 cells by fluorescence microscopy and immunocytochemistry as described previously.
2 Plasmids were grown in E. coli strain DH5␣ and purified using Qiagen Plasmid Maxi Kits (Qiagen, Hilden, Germany). E1-and E3-deleted adenoviral vectors expressing mTRP2, hTRP2, or EGFP have been described. 2, 3, 15 An adenovirus expressing the fusion protein EGFP.mTRP2 (Ad-EGFP.mTRP2) was constructed through Cre-lox recombination with reagents generously provided by Dr S Hardy (Somatix, Alameda, CA, USA). 21 Adenoviruses were propagated on 293 cells, purified by cesium chloride density gradient centrifugation and subsequent dialysis according to standard protocols, and stored at -70°C. All vectors express only the antigen of interest under the CMV immediate-early promoter.
Genetic immunization of mice
Genetic immunization using the gene gun has been performed as described previously. 2, 3 Briefly, plasmid DNA was precipitated on to 1.6-m gold particles at a density of 2 g of DNA per mg of particles. For immunizations, shaved skin of the abdomen was bombarded in vivo by two shots with the Helios gene gun (BioRad, Munich, Germany) at a pressure of 400 psi resulting in the delivery of approximately 1 mg gold carrying 2 g plasmid DNA. Immunizations were repeated weekly for 5 weeks. Genetic immunization with recombinant adenovirus was performed by one intraperitoneal injection of 5 × 10 8 p.f.u. recombinant adenovirus resuspended in 0.2 ml PBS.
Antibody measurements
Antibodies against EGFP, present in serum samples, obtained from mice after genetic immunization were measured by ELISA using recombinant EGFP as a solidphase antigen. Briefly, microtiter plates were coated with 5 g/ml protein in carbonate buffer (pH 9.6) for 16 h at 4°C and blocked with PBS containing 3% BSA and 0.05% Tween. Serum samples were serially diluted in PBS containing 1% BSA and 0.05% Tween (assay buffer) and added for 2 h. Bound antibodies were detected using peroxidase-conjugated donkey anti-mouse IgG (Jackson Immunoresearch, Westgrove, PA, USA) at a 1:5000 dilution in assay buffer followed by color development with ABTS substrate system (Sigma, St Louis, MO, USA). Plates were read in an ELISA reader at 405 nm. Alternatively, serum samples were tested for the presence of specific antibodies by Western blot. 293 Cells infected with recombinant adenovirus were solubilized in lysis buffer (20 mm Tris, 150 mm NaCl, 2 mm EDTA, 0.5% NP40, pH 7.5) containing protease inhibitors (Complete Protease Inhibitor Cocktail, Roche, Germany) 30 h after infection. Cell extracts were subjected to 10% SDS-PAGE and electroblotted on to PVDF membranes. Membranes were blocked with 5% nonfat dry milk in T-PBS (0.1% Tween 20 in PBS) for 2 h and reacted with pooled sera from groups of immunized mice at a 1:200 dilution in T-PBS + 2% nonfat dry milk for 1 h. Bound antibodies were detected with 1:5000 dilutions of peroxidase-conjugated goat anti-mouse IgG (Jackson Immunoresearch) in T-PBS + 2% nonfat dry milk for 1 h and visualized using chemiluminescence on X-ray film (Amersham, Freiburg, Germany).
ELISPOT assays
The induction of peptide-specific T cells was measured using the ELISPOT technique. Briefly, splenocytes were harvested 2 to 4 weeks after immunization and red blood cells depleted. 10 6 splenocytes/well were restimulated in 200 l of CM containing 1 g/ml synthetic peptide and 25 IU/ml rhIL-2 in Millipore HA plates which were coated overnight with 10 g/ml (50 l/well) of antimIFN␥ mAb (R4-6A2; Pharmingen, Heidelberg, Germany) in PBS. After 22 h, cells were washed out of the plates and bound cytokines visualized by incubation with 2.5 g/ml (50 l/well) of biotinylated anti-mIFN␥ mAb (XMG1.2; Pharmingen) for 1.5 h at 37°C, followed by 100 l/well streptavidin-peroxidase (Roche, 1:1500 dilution in PBS containing 1% BSA, and 0.05% Tween 20) for 30 min at RT, and premixed peroxidase substrate kit DAB (Vector Laboratories, Heidelberg, Germany). The number of spots was counted under a dissecting microscope and expressed as mean number of spots of repeated duplicate or triplicate determinations. All experiments were performed between three and five times.
Tumor protection assays
The induction of antitumor immunity was assessed 2 to 4 weeks after immunization. Mice were challenged by intravenous injection of 4 × 10 5 B16 melanoma cells which experimentally induces heavily pigmented lung metastases. The number of macroscopically visible metastases on the surface of the lungs was counted with the help of a dissecting microscope 14 days after challenge. All experiments included four to six mice per group and were performed three or four times.
Statistical analyses
Significant differences of tumor growth were assessed by Student's t test. The difference between groups was conGene Therapy sidered statistically significant when the P value was lower than 0.05.
